In the SMA-560 mouse model of glioma, neutralization of CTLA-4 with monoclonal antibody, 9H10, confers a long-term survival benefit in 80% of treated mice with re-establishment of normal CD4 counts concomitant with a decreased Treg fraction. This evidence concerns the gene CD4 and central nervous system cancer.